Trials / Recruiting
RecruitingNCT06575868
Myo-inositol During Pregnancy to Prevent Gestational Diabetes
Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tufts Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM). This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Myo-inositol | Patients would begin taking myoinositol upon recruitment |
| DIETARY_SUPPLEMENT | Myo-inositol placebo | Patients would begin taking placebo upon recruitment |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2024-08-28
- Last updated
- 2025-04-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06575868. Inclusion in this directory is not an endorsement.